Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Cognitive impairments associated with T2DM are attracting increasing attention and are becoming a highly relevant area of study
Kushner RF, Almandoz JP, Rubino
GLP-1 (glucagon-like peptide-1) helps regulate blood sugar, reduce appetite, and increase feelings of fullness, making it easier for patients to manage their weight
Cardiovascular Risk Reduction Semaglutide SELECT trial (17,604 patients) demonstrated 20% MACE reduction in overweight/obese adults with established CVD
With an increasing number of similar GLP-1 drugs now being used in clinical practice, for conditions ranging from type 2 diabetes and obesity to kidney disease, our findings highlight the potential for these existing drugs to be repurposed to treat the risk of no-reflow in heart attack patients, offering a potentially life-saving solution, said University College London Professor David Atwell
Once the drug is removed, the metabolic conditions that caused weight gain tend to reassert themselves
